3-[3-(4-Methoxyphenyl)prop-2-enoyl]-4-phenyl-1,3-oxazolidin-2-one

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: 3-[3-(4-Methoxyphenyl)prop-2-enoyl]-4-phenyl-1,3-oxazolidin-2-one
• 化学式: C₁₉H₁₇NO₄
• 分子量: 323.3
• InChiKey: GBGFAQKKLKORQI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.16
• 拓扑面积：
  55.8
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• [EN] 5-MEMBERED AZA-HETEROCYCLIC CONTAINING DELTA-OPIOID RECEPTOR MODULATING COMPOUNDS, METHODS OF USING AND MAKING THE SAME<br/>[FR] COMPOSÉS MODULATEURS DU RÉCEPTEUR DELTA DES OPIOÏDES CONTENANT DES AZA-HÉTÉROCYCLES À 5 CHAÎNONS, LEURS PROCÉDÉS D'UTILISATION ET DE FABRICATION
  申请人：TREVENA INC

  公开号：WO2018152293A1

  公开（公告）日：2018-08-23

  The present embodiments are directed, in part, to compounds, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof for modulating the activity of delta opioid receptor, biased and/or unbiased, and/or methods for treating pain, migraines, headaches, depression, Parkinsons Disease, anxiety, and/or overactive bladder, and other disorders and conditions described herein or any combination thereof.

  本实施例部分涉及化合物、其药用可接受盐、或用于调节δ阿片受体活性的药物组合物，包括有偏向性和/或无偏向性的组合物，以及用于治疗疼痛、偏头痛、头痛、抑郁症、帕金森病、焦虑和/或膀胱过度活跃等疾病和症状的方法，以及本文中描述的其他疾病和症状或任何其组合。
• 5-MEMBERED AZA-HETEROCYCLIC CONTAINING DELTA-OPIOID RECEPTOR MODULATING COMPOUNDS, METHODS OF USING AND MAKING THE SAME
  申请人：Trevena, Inc.

  公开号：US20210061790A1

  公开（公告）日：2021-03-04

  The present embodiments are directed, in part, to compounds, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof for modulating the activity of delta opioid receptor, biased and/or unbiased, and/or methods for treating pain, migraines, headaches, depression, Parkinsons Disease, anxiety, and/or overactive bladder, and other disorders and conditions described herein or any combination thereof.
• DIHYDROISOQUINOLINE-2(1H)-CARBOXAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS
  申请人：GOSSAMER BIO SERVICES, INC.

  公开号：US20210139484A1

  公开（公告）日：2021-05-13

  The invention provides dihydroisoquinoline-2(1H)-carboxamide and related compounds, pharmaceutical compositions, and their use in the treatment of medical conditions, such as cancer, and in inhibiting HPK1 activity.